cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Aligos Therapeutics Inc
3 own
11 watching
Current Price
$1.75
$-0.17
(-8.85%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
74.93M
52-Week High
52-Week High
3.17
52-Week Low
52-Week Low
0.8401
Average Volume
Average Volume
0.18M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization74.93M
icon52-Week High3.17
icon52-Week Low0.8401
iconAverage Volume0.18M
iconDividend Yield--
iconP/E Ratio--
What does the Aligos Therapeutics Inc do?
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB. The company also develops ALG-020572, an antisense oligonucleotide to prevent HBsAg translation and secretion; and ALG-055009, a small molecule THR-ß agonist that is in the Phase 1a/1b for the treatment of non-alcoholic steatohepatitis(NASH). In addition, it develops siRNA drug candidate, ALG-125755, as well as ALG-125097 and ALG-125819, demonstrated potent inhibition of HBsAg release from HBV-infected cells. It has entered into license and collaboration agreements with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; Emory University to provide hepatitis B virus capsid assembly modulator technology; research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors; and Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH. The company was incorporated in 2018 and is headquartered in South San Francisco, California.
Read More
How much money does Aligos Therapeutics Inc make?
News & Events about Aligos Therapeutics Inc.
Globe Newswire
30days ago
Final cohort of Phase 1 study projected to be complete in H1 2023 Phase 2-enabling GLP toxicology studies projected to be complete in H2 2023 Clinical update on all pipeline programs to be presented at the 2023 J.P. Morgan Healthcare Conference on January 12 at 10:30 a.m. PT SOUTH SAN FRANCISCO, ...
Globe Newswire
1month ago
Coronavirus protease inhibitor, ALG-097558, has demonstrated antiviral activity in vivo and promising pan-coronavirus activity in vitroFirst-in-human studies anticipated to begin in H1 2023 SOUTH SAN FRANCISCO, Calif., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a ...
Globe Newswire
3 months ago
ALG-055009, aTHR-agonist drug candidate in development as a treatment for NASH, demonstrated dose-dependent reductions in several atherogenic lipids and a favorable pharmacokinetic profile in subjects with hyperlipidemia Aligos oral and poster presentations also collectively highlight new data from ...
Globe Newswire
3 months ago
Reductions in hepatitis B surface antigen levels observed in a subset of subjects with chronic hepatitis B enrolled in Phase 1 study ALG-000184-201SOUTH SAN FRANCISCO, Calif., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company ...
Globe Newswire
3 months ago
SOUTH SAN FRANCISCO, Calif., Oct. 21, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced seven upcoming poster presentations...
Frequently Asked Questions
Frequently Asked Questions
What is Aligos Therapeutics Inc share price today?
plus_minus_icon
Can Indians buy Aligos Therapeutics Inc shares?
plus_minus_icon
How can I buy Aligos Therapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Aligos Therapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Aligos Therapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Aligos Therapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Aligos Therapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Aligos Therapeutics Inc?
plus_minus_icon
What percentage is Aligos Therapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Aligos Therapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$1.75
$-0.17
(-8.85%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00